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CD4
 
 
 
CD25
 
 
 
 regulatory T (T reg) cells play a pivotal role in control of the immune response. 
Transforming growth factor-
 
 
 
 (TGF-
 
 
 
) has been shown to be required for T reg cell activity; 
however, precisely how it is involved in the mechanism of suppression is poorly understood. 
Using the T cell transfer model of colitis, we show here that CD4
 
 
 
CD45RB
 
high
 
 T cells that 
express a dominant negative TGF-
 
 
 
 receptor type II (dnT
 
 
 
RII) and therefore cannot respond 
to TGF-
 
 
 
, escape control by T reg cells in vivo. CD4
 
 
 
CD25
 
 
 
 T reg cells from the thymus of 
dnT
 
 
 
RII mice retain the ability to inhibit colitis, suggesting that T cell responsiveness to 
TGF-
 
 
 
 is not required for the development or peripheral function of thymic-derived T reg 
cells. In contrast, T reg cell activity among the peripheral dnT
 
 
 
RII CD4
 
 
 
CD25
 
 
 
 population is 
masked by the presence of colitogenic effector cells that cannot be suppressed. Finally, we 
show that CD4
 
 
 
CD25
 
 
 
 T reg cells develop normally in the absence of TGF-
 
 
 
1 and retain the 
ability to suppress colitis in vivo. Importantly, the function of TGF-
 
 
 
1
 
 
 
/
 
 
 
 T reg cells was 
abrogated by anti–TGF-
 
 
 
 monoclonal antibody, indicating that functional TGF-
 
 
 
 can be 
provided by a non–T reg cell source.
 
Naturally occurring regulatory T (T reg) cells
mediate a nonredundant role in control of the
immune response. Among these populations,
the most well-characterized are those con-
tained within the CD4
 
 
 
CD25
 
 
 
 subset (1–3).
Although initially identified for their ability to
prevent autoimmune disease (4), CD4
 
 
 
CD25
 
 
 
T reg cells are now known to mediate a more
general suppressive role, acting to limit immune
pathology in the face of chronic immune stimu-
lation (5–8).
Even though the list of immune responses
affected by CD4
 
 
 
CD25
 
 
 
 T reg cells continues
to expand, their mechanism of action remains
obscure. Attention has focused on the role of
cell contact–dependent mechanisms and the
actions of immunoregulatory cytokines such as
IL-10 and TGF-
 
 
 
 (1). The relative contribution
of these different mechanisms to suppressor
function is highly controversial and may vary
depending on the nature of the immune re-
sponse being regulated. For example, TGF-
 
 
 
appears to play a nonredundant role in control
of intestinal inflammation and diabetes (6, 9,
10), but not gastritis (11). A proportion of
CD4
 
 
 
CD25
 
 
 
 cells express TGF-
 
 
 
1 on their
surface (12) and this has been implicated in
their suppressor function in vitro. However,
TGF-
 
 
 
1
 
   
 
 CD4
 
 
 
CD25
 
 
 
 cells retain T reg
cell activity in vitro, indicating that TGF-
 
 
 
1
synthesis by CD4
 
 
 
CD25
 
 
 
 cells is not essential
for cell contact–dependent suppression (11).
The TGF-
 
 
 
s, encompassing TGF-
 
 
 
1,
TGF-
 
 
 
2, and TGF-
 
 
 
3, are highly pleiotropic
cytokines with diverse effects on many devel-
opmental and physiological processes. TGF-
 
 
 
1
is the most abundant form in lymphoid organs
and has a number of effects on cells of the im-
mune  system, including inhibition of T cell
proliferation and differentiation and negative
effects on macrophage activation and DC mat-
uration (for review see reference 13). It plays a
pivotal role in immune regulation as TGF-
 
 
 
1
 
   
 
 mice develop a multi-organ inflamma-
tory disease (14, 15). Recently, TGF-
 
 
 
1 has
been shown to act as a costimulatory factor for
expression of FoxP3 (16), leading to the differ-
entiation of CD4
 
 
 
CD25
 
 
 
 T reg cells from pe-
ripheral CD4
 
 
 
CD25
 
 
 
 progeny (17, 18). These
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results raise the possibility that, in addition to playing a role
in the effector function of T reg cells, TGF-
 
 
 
 also stimulates
their differentiation. The broad immunoregulatory proper-
ties of TGF-
 
 
 
1 fit well with its involvement in the function
of T reg cells; however, its precise role is unknown. It re-
mains to be established whether T reg cells themselves are
the crucial cellular source of TGF-
 
 
 
1 and, furthermore,
which are the important cellular targets. Answers to these
questions are complicated by the fact that both TGF-
 
 
 
1 and
its receptor are expressed by many different cell types.
TGF-
 
 
 
1 binds to the TGF-
 
 
 
RI and RII heterodimeric
receptor and induces signaling via activation of the Smad
pathway. Recently, mice with T cell–restricted expression of
a dominant negative form of the TGF-
 
 
 
RII have been gen-
erated (dominant negative TGF-
 
 
 
 receptor II [dnT
 
 
 
RII];
references 19, 20). In these mice, the transgenic (Tg) TGF-
 
 
 
RII has a truncated intracellular kinase domain and there-
fore retains cytokine binding activity, but fails to trigger
downstream signaling events. Unlike TGF-
 
 
 
1
 
   
 
 mice that
develop an inflammatory disease within the first weeks of
life, dnT
 
 
 
RII mice survive into adulthood. However, these
mice do show an accumulation of activated T cells and suc-
cumb to an inflammatory disease at 
 
 
 
12 wk of age, indicat-
ing the physiological significance of TGF-
 
 
 
 signaling in T
cell homeostasis.
In this paper, we have used cells from dnT
 
 
 
RII and
TGF-
 
 
 
1–deficient mice in the T cell adoptive transfer
model of colitis (21, 22) to further dissect the role of TGF-
 
 
 
1 in the function of CD4
 
 
 
CD25
 
 
 
 T reg cells. Our results
show that the function of T reg cells requires the direct ac-
tion of TGF-
 
 
 
 on pathogenic T cells and that in the absence
of this interaction, colitogenic T cells escape T reg cell–
mediated control. In addition, we provide evidence that the
CD4
 
 
 
CD25
 
 
 
 T reg cell pool in the thymus is fully func-
tional in the absence of TGF-
 
 
 
 signaling, but that peripheral
dnT
 
 
 
RII CD4
 
 
 
CD25
 
 
 
 cells induce rather than prevent
colitis. Finally, we demonstrate that CD4
 
 
 
CD25
 
 
 
 T reg
cells from TGF-
 
 
 
1–deficient mice retain the ability to pre-
vent the development of colitis, even though T reg cell ac-
tivity remains TGF-
 
 
 
 dependent.
Figure 1. CD4 CD25  T cells are unable to prevent colitis induced 
by transfer of dnT RII CD4 CD45RBhigh cells. RAG-1    mice received 
2   105 CD4 CD45RBhigh cells isolated from either WT or dnT RII mice. In 
addition, some mice also received an equivalent number of WT CD4 CD25  
T cells. (A) Data show the mean weight of six animals per group and are 
representative of three independent experiments. Numbers in parentheses 
indicate number of animals with clinical signs of disease killed at day 45 
and weights for these animals are included in the mean weights. CD4 CD25  
cells confer significant protection from wasting induced by WT 
CD4 CD45RBhigh cells (P   0.03) but fail to prevent progressive weight 
loss induced by dnT RII CD4 CD45RBhigh cells (NS). (B) Incidence and 
severity of colitis at the time of sacrifice. (n) Number of mice in each 
group. Data are pooled from three independent experiments. CD4 CD25  
cells confer significant protection from colitis induced by WT 
CD4 CD45RBhigh cells (P   0.001), but fail to prevent colitis induced by 
dnT RII CD4 CD45RBhigh cells (NS). (C) Representative photomicrographs 
of distal colon of RAG-1    mice after transfer of CD4  T cells. Original 
magnification, 250 (hematoxylin and eosin).JEM VOL. 201, March 7, 2005 739
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RESULTS
Pathogenic T cells must respond to TGF-  for 
suppression of colitis
To determine whether TGF-  has direct effects on the coli-
togenic T cell population in vivo, we compared the abil-
ity of CD4 CD25  cells to inhibit colitis induced by
CD4 CD45RBhigh cells isolated from WT or dnT RII
mice. T cell populations were isolated from 6–8-wk-old
dnT RII mice before the development of inflammatory dis-
ease. At this time, the frequency of CD4  cells expressing
high levels of CD45RB was similar in dnT RII and WT
controls (unpublished data). To probe the relative ability of
these populations to induce colitis, CD4 CD45RBhigh cells
isolated from either WT or dnT RII mice were transferred
to syngeneic RAG-1    recipients. As shown in Fig. 1 A,
the kinetics of the wasting disease was similar regardless of
the genotype of the donor cells and the majority of mice in
both groups developed colitis, although the incidence of se-
vere disease was reduced in mice transfused with dnT RII
cells (Fig. 1, B and C). As dnT RII mice develop colitis
later in life (19), this latter finding may be the consequence
of a reduction in potentially colitogenic cells in the naive
(CD45RBhigh) pool and their transition into an antigen-
experienced (CD45RBlow) phenotype (23).
The aforementioned data indicate a somewhat re-
duced colitogenic potential among the dnT RII CD4 
CD45RBhigh T cell population compared with WT controls.
Despite this, although CD4 CD25  T reg cells were suffi-
cient to inhibit the development of wasting disease and coli-
tis induced by WT CD4 CD45RBhigh cells, they failed to
prevent pathology induced by transfer of dnT RII Tg cells
(Fig. 1). Indeed, mice that received a mixture of WT
CD4 CD25  T cells and dnT RII CD4 CD45RBhigh T
cells exhibited a similar incidence and severity of colitis to
those that received dnT RII CD4 CD45RBhigh T cells
alone (Fig. 1). These results are consistent with a require-
ment for TGF-  for prevention of colitis by T reg cells and,
in addition, show that TGF-  signaling on the potentially
colitogenic T cell population is a crucial part of the mecha-
nism of immune suppression.
TGF-  inhibits Th1 cell accumulation and effector function
TGF- 1 has potent negative regulatory effects on CD4  T
cells in vitro, by inhibiting their proliferation, differentiation,
and effector function (13). To further investigate how TGF- 
acting on CD4 CD45RBhigh cells in vivo is able to pre-
vent colitis, regulatory and pathogenic populations were iso-
lated from congenic mice expressing different alleles of
CD45. As described previously (24), transfer of WT
CD4 CD45RBhigh cells to RAG-1    mice led to accumu-
lation of IFN- –secreting Th1 cells in the colon (Fig. 2). A
similar accumulation of IFN-   cells was also observed after
transfer of dnT RII CD4 CD45RBhigh cells. Cotransfer of
CD4 CD25  T cells inhibited the accumulation of WT
CD4 CD45RBhigh cells in the colon and also reduced the
frequency of those cells capable of secreting IFN-  (Fig. 2).
In contrast, T reg cell transfer had no effect on the ability of
dnT RII CD4 CD45RBhigh progeny to differentiate into
Th1 cells or accumulate in the intestine. Together, these
data suggest that an essential part of CD4 CD25  T reg cell
activity in vivo requires the ability of TGF-  to act directly
on pathogenic T cells to suppress their accumulation and ef-
fector function.
Peripheral CD4 CD25  cells that cannot respond to TGF-  
fail to suppress colitis
As TGF-  has been shown to induce the differentiation of
CD4 CD25  T reg cells from naive precursors (17), it is
possible that immune pathology in dnT RII mice also re-
flects deficiencies in the development, differentiation, or
function of CD4 CD25  T reg cells. To assess this, a phe-
notypic and functional analysis of the CD4 CD25  T cells
from the spleen and thymus of young 4–6-wk-old dnT RII
mice was performed. CD4 CD25  cells appeared to de-
velop normally in the absence of TGF-  signaling and were
present at a similar frequency in the thymus of WT and
dnT RII mice. There was a small increase in the proportion
Figure 2. Cytokine production by the progeny of transferred 
CD4 CD45RBhigh cells isolated from the LP. RAG-1 /  mice received 
CD4  T cells as described in Fig. 1. 6–8 wk after transfer, LP cells were 
isolated and stimulated for 18 h with plate-bound anti-CD3 antibody. 
(A) Levels of cytokine expression were determined by flow cytometry. 
Scatter plots are gated on CD4 CD45.1  lymphocytes to identify progeny 
of transferred CD4 CD45RBhigh cells and are representative of four to five 
mice per group. (B) Absolute numbers of cytokine-producing cells were 
determined by multiplying the frequency of cytokine producing cells after 
stimulation in vitro by the total number of LP leukocytes. Data are pooled 
from two independent experiments.TGF-  AND T REG CELL FUNCTION | Fahlén et al. 740
of CD4 CD25  cells in the spleen of dnT RII mice (Fig.
S1, available at http://www.jem.org/cgi/content/full/
jem.20040685/DC1); however, there was no significant
change in the activation status of these cells as expression
of CD62L, CD45RB, and CD69 was similar to WT
CD4 CD25  cells (unpublished data). T reg cell activity
was clearly present within the splenic dnT RII CD4 
CD25  pool as this population was able to inhibit T cell
proliferation in vitro with similar efficiency to WT CD4 
CD25  cells (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20040685/DC1).
Despite the presence of demonstrable T reg cell activity
within the splenic dnT RII CD4 CD25  population, these
cells behaved very differently in vivo when compared with
WT CD4 CD25  cells. First, dnT RII CD4 CD25  sple-
nocytes failed to provide statistically significant protection
from CD4 CD45RBhigh–induced colitis even when isolated
from young (3–4 wk old) mice and, second, they induced
colitis themselves when transferred alone to RAG-1    mice
(Fig. 3). The lack of apparent T reg cell activity in vivo
amongst splenic dnT RII CD4 CD25  cells was not attrib-
utable to impaired thymic development of CD4 CD25  T
reg cells as dnT RII CD4 CD25  thymocytes, like their
WT counterparts, were able to suppress colitis (Fig. 3). Thy-
mic-derived dnT RII CD4 CD25  cells accumulated in
the spleen and MLN of CD4 CD45RBhigh–restored RAG-
1    mice (unpublished data), indicating that responsiveness
to TGF-  is not required for the peripheral accumulation or
function of CD4 CD25  cells.
The ability of splenic dnT RII CD4 CD25  cells to
induce rather than inhibit colitis is consistent with the find-
ing that potentially colitogenic CD4 CD45RBhigh cells
from dnT RII are not controlled by T reg cells and most
likely reflects an accumulation of activated colitogenic effec-
tor cells that are refractory to suppression. However, as
TGF- 1 can induce FoxP3 expression amongst peripheral
CD4  T cells (17, 18), it is also possible that the lack of T
reg cell activity is due to a deficiency of FoxP3  cells
amongst the splenic dnT RII CD4 CD25  pool. Quantifi-
cation of FoxP3 mRNA expression revealed no significant
differences between splenic CD4 CD25  cells isolated from
dnT RII and WT mice (Fig. 4 A). This was confirmed at a
single cell level, as the frequency of CD4  cells in the spleen
expressing FoxP3 protein was similar in dnT RII and WT
mice (Fig. 4 B). FoxP3  cells were also abundant in the
spleen and MLN of colitic RAG-1    mice that had re-
ceived dnT RII CD4 CD25  cells 8 wk earlier, indicating
that the development of colitis was not a consequence of the
inability of dnT RII FoxP3  cells to accumulate in vivo
(unpublished data).
Together, the data demonstrate that responsiveness to
TGF-  is not essential for the development or function of
naturally arising CD4 CD25  T reg cells. These cells are
present in the thymus of dnT RII mice and retain the abil-
ity to function in the periphery and suppress colitis in the T
cell transfer model. FoxP3  cells are present in normal fre-
quency amongst splenic dnT RII CD4  cells; however,
their activity is masked by the presence of colitogenic effec-
Figure 3. Suppression of colitis by thymic but not splenic dnT RII 
CD4 CD25  cells. RAG-1    mice received 2–4   105 CD4 CD45RBhigh 
cells alone or in combination with 1.5–2   105 CD4 CD25  cells isolated 
from the spleen or thymus of either WT or dnT RII Tg mice. In addition, 
some mice received splenic CD4 CD25  cells alone. Mice were killed 6–8 wk 
after transfer, and colons were taken for histological analysis. Data show 
colitis scores for individual mice taken from three independent experiments.
Figure 4. CD4 CD25  cells from dnT RII mice express normal 
levels of FoxP3. (A) CD4 CD25  and CD4 CD25  cells were isolated 
from spleens of WT (white bars) and dnT RII (black bars) mice. mRNA was 
recovered and analyzed for expression of FoxP3 and CD3  by quantitative 
real-time PCR. Data show FoxP3 mRNA expression normalized to CD3  
levels as mean   SEM for triplicate wells. A second experiment gave simi-
lar results. (B) Tissue sections from spleens of WT and dnT RII mice were 
stained for CD4 (green) and FoxP3 (red). FoxP3 CD4  cells show red 
nuclear staining and green surface staining. Frequency of FoxP3  cells 
among CD4  cells: WT 6.4   1.3% and dnT RII 6.6   1.1%. Numbers 
represent mean and SEM from three individual mice per group. Original 
magnification, 200.JEM VOL. 201, March 7, 2005 741
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tor cells that express CD25 and are refractory to T reg cell–
mediated control.
TGF- 1 /  CD4 CD25  T reg cells are fully 
functional in vivo
There is conflicting data concerning the role of TGF- 1 in
the suppressive activity of CD4 CD25  T reg cells in vitro.
Some investigators report high levels of TGF- 1 produced
by and bound to the surface of activated CD4 CD25  cells
and that blockade of TGF-  is sufficient to abrogate
CD4 CD25  T reg cell–mediated suppression (12). In con-
trast, others have failed to find any requirement for T reg
cell–derived TGF- 1 in vitro (11). As TGF-  is required for
suppression of CD4 CD45RBhigh cell–induced colitis (6, 9),
we examined whether CD4 CD25  cells themselves are the
critical source of TGF- 1 in this model. This approach was
confounded by the fact that TGF- 1    mice develop a fatal
lymphoproliferative inflammatory disease early after birth
and fail to survive beyond 3–4 wk of age (14, 15). As a re-
sult, the CD25  pool in these mice is likely to be highly dis-
torted, containing an elevated frequency of activated effector
cells. To circumvent this, CD4 CD25  cells were isolated
from BALB/c TGF- 1    mice that had been crossed onto
the BALB/c DO11.10 TCR Tg line (DO11.10.TGF- 1   ).
In these mice, the reduced T cell receptor diversity prevents
the early onset of the multi-organ inflammatory disease and
mice survive beyond 12 wk (unpublished data).
In concordance with a previous paper (25), functional
CD4 CD25  cells were present in DO11.10 mice with ap-
proximately half expressing the clonotypic T cell receptor,
identified by KJ-1.26 (Fig. 5). A somewhat higher frequency
of CD4 CD25  cells was present in DO11.10.TGF- 1   
mice, but a similar proportion of these expressed the Tg
TCR (Fig. 5). There was no statistically significant difference
in the frequency of activated CD62Llow cells present amongst
the CD4 CD25  population from DO11.10.TGF- 1   
mice (47.5%   2.3; n   6) compared with the equivalent
population from DO11.10 TGF- 1    mice (36.4%   3.9;
n   6). Importantly, expression of FoxP3 mRNA was also
identical between groups, suggesting no significant change in
the development of naturally arising FoxP3 CD4 CD25  T
reg cells in the absence of TGF- 1 (Fig. S3, available at http:
//www.jem.org/cgi/content/full/jem.20040685/DC1). Con-
sistent  with this, DO11.10.TGF- 1   CD4 CD25  cells
were able to suppress antigen-induced T cell activation in
vitro with similar potency to DO11.10.TGF- 1    CD4 
CD25  cells (unpublished data). To analyze functional
activity in vivo, CD4 CD25  cells from DO11.10 or
DO11.10.TGF- 1    mice were transferred either alone or
together with BALB/c CD4 CD45RBhigh cells into C.B-
17 SCID mice. Strikingly and contrary to expectation,
DO11.10.TGF- 1    CD4 CD25  cells were able to pre-
vent colitis similarly to the equivalent population taken from
DO11.10 mice (Fig. 6, A and B). The accumulation of
DO11.10.TGF- 1    CD4 CD25  progeny in vivo after
transfer was indistinguishable from CD4 CD25  cells iso-
lated from DO11.10 TGF- 1    mice (unpublished data).
These results provide unequivocal evidence that CD4 
CD25  cells can develop in the complete absence of TGF-
 1 and, despite being unable to synthesize this cytokine, re-
tain suppressor function in vivo.
Suppression by TGF- 1 /  T reg cells remains 
TGF-  dependent
It is possible that TGF- 1    CD4 CD25  T reg cells, hav-
ing developed in a TGF- 1–deficient environment, are able
to use other factors to control the development of colitis.
To test this, C.B-17 SCID mice received WT CD4 
CD45RBhigh cells, together with CD4 CD25  cells from
either WT, DO11.10, or DO11.10 TGF- 1    mice. Some
mice also received an anti–TGF-  mAb. Significantly, ad-
ministration of anti–TGF-  mAb abrogated suppression of
colitis mediated not only by WT CD4 CD25  cells (Fig. 6
and reference 6) and DO11.10 CD4 CD25  cells (unpub-
lished data), but also by DO11.10 TGF- 1    CD4 CD25 
T reg cells (Fig. 6). Together, these data show that TGF- 
plays a crucial role in CD4 CD25  T reg cell–mediated
suppression of colitis, even when the TGF- 1 is not pro-
duced by the CD4 CD25  T reg cell.
DISCUSSION
There is now accumulating evidence that TGF-  is an im-
portant mediator of T reg activity in vivo (1). However, it
remains to be established precisely how TGF-  is involved
in T reg function: specifically, which cells are the targets of
TGF-  signaling and whether the CD4 CD25  T reg cell
population is an important source of this cytokine. Combin-
ing the T cell transfer model of colitis with the use of dnT-
 RII mice, we provide evidence that suppression of colitis
by CD4 CD25  T reg cells requires the direct action of
Figure 5. Frequency of KJ-1.26  cells is similar among 
CD4 CD25  cells from either DO11.10 or DO11.10 TGF- 1 /  
mice. Mice analyzed at 6–8 wk of age. CD4 enriched splenocytes from 
either DO11.10 or DO11.10 TGF- 1    mice were analyzed by flow cy-
tometry for the expression of CD4 and CD25. Numbers indicate percentage 
of CD25  cells among CD4  cells. CD4 CD25  cells were further analyzed 
for the expression of the clonotypic TCR by mAb KJ-1.26. Numbers indi-
cate percentage KJ-1.26  cells among CD4 CD25  cells. Data are repre-
sentative of six mice per group.TGF-  AND T REG CELL FUNCTION | Fahlén et al. 742
TGF-  on the colitogenic T cell population, where it serves
to prevent the accumulation of Th1 effector cells in the co-
lon. This conclusion is further supported by the finding that
colitogenic T cells accumulate in the peripheral CD4 
CD25  pool of dnT RII mice. Significantly, responsiveness
to TGF-  is not required for the development or function
of thymic CD4 CD25  T reg cells. However, although
FoxP3  cells are present in the peripheral CD4 CD25 
pool from dnT RII mice, it was not possible to measure the
T reg cell activity in vivo due to the presence of pathogenic
T cells that are refractory to T reg cell–mediated control. In
addition, CD4 CD25  T reg cells from TGF- 1    mice
retain the ability to prevent colitis. Under these circum-
stances, suppression is still abrogated by administration of
anti–TGF-  mAb indicating the following: (a) TGF-  re-
mains central to the function of CD4 CD25  T reg cells
even when they cannot synthesize this cytokine themselves
and (b) sufficient TGF- 1 can be provided by cellular
sources other than the T reg cell population.
In the absence of TGF-  signaling in T cells, dnT RII
mice develop inflammatory infiltrates in the lung and colon
with circulating autoantibodies, indicating that T cell re-
sponsiveness to TGF-  is required for normal immune ho-
meostasis (19). The ability of TGF-  to directly suppress T
cell responses may be a consequence of its ability to inhibit
effector T cell differentiation (26, 27), to stimulate T reg cell
function and expansion (17, 28–30), or a combination of
both of these activities. In our work, transfer of CD4 
CD45RBhigh cells from dnT RII mice into RAG-1    mice
led to the development of wasting disease and colitis even in
the presence of a dose of CD4 CD25  T reg cells capable of
preventing colitis induced by WT CD4 CD45RBhigh cells.
These results provide the first evidence in vivo that the ab-
sence of a functional TGF-  receptor on pathogenic CD4 
T cells renders them refractory to control by CD4 CD25 
T reg cells. Similar to these results, in a model of diabetes,
CD8  T cells from dnT RII mice showed enhanced diabe-
togenic potential and escaped control by CD4 CD25  T
reg cells (31). Together, these results demonstrate that the
function of CD25  T reg cells is critically dependent on the
direct inhibitory effects of TGF-  on potentially pathogenic
T cells.
The inability of CD4 CD25  T reg cells to suppress
dnT RII CD4 CD45RBhigh cells in vivo does not seem to
be attributable to a general hyperreactivity of the colitogenic
population, but rather to their refractoriness to suppression.
Several lines of evidence support this conclusion. First, WT
and dnT RII CD4 CD45RBhigh cells induced wasting dis-
ease in RAG-1    recipients with similar kinetics. Second,
the incidence and severity of colitis was somewhat reduced
in mice restored with dnT RII CD45RBhigh cells, arguing
against enhanced pathogenicity of these cells. Finally, dnT-
 RII CD4 TCR Tg T cells do not show hyperreactivity
and exhibit a similar dose response curve upon antigen-
induced activation (unpublished data).
TGF- 1 has been shown to inhibit T cell responses in
vitro at several levels. It acts on naive T cells to inhibit ex-
pression of T-bet, a transcription factor critical for the devel-
opment of a Th1 phenotype (27, 32) and has also been
shown to inhibit IFN-  secretion by Th1 effector cells (26,
33). TGF- –dependent suppression by CD4 CD25  T reg
cells is associated with a reduction not only in the number of
T cells in the colon but also in the frequency of those that
can produce IFN-  at this site. As such, TGF-  may also act
Figure 6. CD4 CD25  T cells from DO11.10.TGF- 1 /  mice retain 
the ability to suppress colitis. C.B-17 SCID mice received 4   105 
CD4 CD45RBhigh cells alone or in combination with 105 CD4 CD25  cells 
isolated from 6–8-wk-old WT, DO11.10, or DO11.10.TGF- 1    mice. 
Some mice received anti–TGF-  mAb. (A) Incidence and severity of colitis 
at time of sacrifice. (n) Number of mice in each group. Data are pooled 
from five independent experiments. CD4 CD25  cells from WT, DO11.10, 
and DO11.10 TGF- 1    mice confer significant protection from colitis 
(P   0.02, P   0.01, and P   0.002, respectively). Mice receiving 
CD4 CD45RBhigh cells together with CD4 CD25  cells from DO11.10 
TGF- 1    mice are significantly different from mice that in addition 
received anti–TGF-  mAb once a week (P   0.007). (B–D) Representative 
photomicrographs of colon from C.B-17 SCID mice after transfer of (B) 
CD4 CD45RBhigh cells, (C and D) CD4 CD45RBhigh, and DO11.10 TGF- 1    
CD4 CD25  cells. (D) Mice treated with anti–TGF-  mAb once a week. 
Original magnification, 200 (hematoxylin and eosin).JEM VOL. 201, March 7, 2005 743
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at several levels in vivo, preventing accumulation of T cells
in the intestine as well as inhibiting the acquisition of effec-
tor function by these cells.
TGF- 1 has been shown to induce FoxP3 expression
and acquisition of T reg function amongst peripheral
CD25 CD4  cells in vitro (16, 17). However, it is un-
known whether this pathway is operational in vivo or
whether TGF- 1 is also involved in the generation of
CD4 CD25  T reg cells in the thymus. To address this, we
analyzed the thymic and peripheral CD4 CD25  T cell
pool in dnT RII mice. Our results show that dnT RII
CD4 CD25  thymocytes express similarly high levels of
FoxP3 mRNA as WT CD4 CD25  cells (unpublished
data). These cells were also fully functional based on their
ability to accumulate in vivo and prevent colitis in the T cell
transfer model, indicating that T cell responsiveness to TGF- 
is not required for the development or peripheral function
of thymic-derived CD4 CD25  T reg cells. In contrast,
peripheral dnT RII CD4 CD25  cells failed to inhibit
CD4 CD45RBhigh-induced colitis and were pathogenic
when transferred alone to RAG-1    recipients. The lack of
demonstrable T reg cell activity in vivo amongst peripheral
dnT RII CD4 CD25  cells was not the consequence of a
complete absence of T reg cells as dnT RII CD4 CD25 
cells expressed similarly high levels of FoxP3 mRNA as WT
CD4 CD25  cells and also retained the ability to suppress T
cell activation in vitro. In addition, the frequency of CD4 
cells expressing FoxP3 protein was similar in dnT RII and
WT CD4  cells. Together, the data suggest that FoxP3  T
reg cells are present among splenic dnT RII CD4 CD25 
cells, but their activity cannot be measured due to the
presence of colitogenic T cells that accumulate in the
CD4 CD25  pool postthymically and cannot be controlled
by T reg cells. As colitogenic T cells in the naive T cell pool
in dnT RII mice are resistant to T reg cell–mediated
control, these cells may be driven into the activated CD4 
CD25  pool by exposure to intestinal antigens in the pe-
riphery (23). The CD4 CD25  pool, even in WT mice,
contains  70% FoxP3  cells, making it likely that the effec-
tor cells reside within the FoxP3  fraction of dnT RII
CD4 CD25  cells. These findings illustrate that the resis-
tance to suppression of pathogenic T cells is an important
factor in determining T reg cell activity and that the mere
presence of FoxP3 CD4 CD25  in an inflammatory lesion
is not necessarily indicative of functional suppression.
CD4 CD25  T reg cells from DO11.10.TGF- 1   
mice retained the ability to prevent colitis, demonstrating
that production of TGF- 1 by T reg cells is not essential for
their function in vivo. These results are consistent with a re-
cent paper that showed that TGF- 1    CD4 CD25  cells
could ameliorate immune pathology induced by transfer of
TGF- 1    CD4 CD25  cells to immune-deficient recipi-
ents (34). Recently, Nakamura et al. found that TGF- 1   
CD4 CD25  cells failed to prevent colitis in the T cell
transfer model. That work was performed on the C57BL/6
background, making it possible that the conflicting results
are attributable to differences in genetic background. Alter-
natively, as Nakamura et al. purified CD4 CD25  from
TGF- 1    mice that develop severe lymphoproliferative
disease early after birth; it cannot be excluded that the func-
tion of T reg cells in that study was obscured by the presence
of colitogenic effector cells in the activated CD4 CD25  T
cell pool. Suppression of colitis by DO11.10.TGF- 1   
CD4 CD25  cells was inhibited by anti–TGF-  mAb, indi-
cating that TGF-  remains central to the function of
CD4 CD25  T reg cells even when they do not synthesize
it themselves. Production and regulation of TGF-  is very
complex. In this instance, it seems likely that TGF- 1   
CD4 CD25  T reg cells act to induce TGF-  production
by other hematopoietic or stromal cells. A wide variety of
cells are capable of producing TGF-  and identifying the
relevant ones in this model, which would require cell type–
specific deletion of TGF-  among key candidates, such as
DCs. It is also worth noting that TGF-  is produced in a la-
tent form that can be found bound to the surface of
CD4 CD25  T reg cells (12). Activation of TGF-  is con-
trolled by the presence of additional factors such as thrombo-
spondin-1 (35–37), making it possible that CD4 CD25  T
reg cells contribute to this activation process. Although
CD4 CD25  T reg cells do not have to synthesize TGF- 
to function in vivo, they may be required to express it on
their surface, focusing it for presentation to effector T cells as
has been described previously (12, 38). Indeed, expression of
membrane-bound latency–associated peptide was found to
identify a population of CD4 CD25  T reg cells capable of
inhibiting colitis (38). An alternative possibility is that TGF-
 1    CD4 CD25  T reg cells function via TGF- 2 secre-
tion. However, the fact that TGF- 1    mice develop severe
immune pathology suggests that TGF- 2 cannot compen-
sate for the role of TGF- 1 in immune regulation.
In summary, this paper identifies T cell responsiveness to
TGF-  as an important factor that determines susceptibility
to control by CD4 CD25  T reg cells. Impaired T cell re-
sponsiveness to TGF-  may be involved in the pathogenesis
of inflammatory bowel disease as intestinal T cells from in-
flammatory bowel disease patients expressed high levels of
the inhibitor of TGF-  signaling Smad 7, allowing them to
escape the inhibitory effects of TGF-  (39).
MATERIALS AND METHODS
Mice and antibodies. C57BL/6, C57BL/6 RAG-1–deficient (RAG-1   ),
C57BL/6.SJL.CD45 congenic mice, and C57BL/6.CD4-restricted dnT RII
(19) as well as BALB/c, DO11.10, DO11.10 TGF- 1–deficient (TGF- 1   ),
and C.B-17 SCID mice were bred under specific pathogen-free conditions
and maintained in microisolator cages with filtered air at the School of Pa-
thology in Oxford and used in experiments between 3 and 8 wk of age. All
procedures were conducted in accordance with the Animals (Scientific Pro-
cedures) Act of 1986.
The following mAbs were used for CD4 enrichment: YTS169 (40),
anti-CD8; TIB120, anti–MHC class II (American Type Culture Collec-
tion); M1/70, anti–Mac-1 (TIB128; American Type Culture Collection);
and RA3-6B2 (41), anti-B220. FITC-conjugated anti-CD45RB (16A);
Cy-Chrome–conjugated anti-CD4 (RM4-5); biotinylated anti-CD25
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gated streptavidin (BD Biosciences) were used for FACS sorting. PerCP-
conjugated anti-CD4 (RM4-5), FITC-conjugated anti-CD4 (RMA4-4),
biotinylated anti-CD45.1 (A20), FITC-conjugated anti-CD45.2 (104), PE-
conjugated anti–TCR-  chain (H57-597), FITC-conjugated anti–IFN- 
(XMG1-2), PE-conjugated anti-CD25 (PC61), allophycocyanin-conju-
gated streptavidin (BD Biosciences), and biotinylated anticlonotypic TCR
(KJ-1.26; reference 42) were used for analysis of T cell populations. Anti–
mouse CD3  (145-2C11) was purified from hybridoma supernatants and
used in proliferation assays in vitro. For in vivo experiments, 1D11.16.8
(anti–mouse TGF- 1/2; reference 43) was purified from hybridoma super-
natant by affinity chromatography and shown to contain  0.1 EU endo-
toxin per milligram of protein.
Purification of T cell subsets. CD4  T cell subsets were isolated from
spleen or thymus as described previously (44). In brief, single cell suspensions
were depleted of CD8 , MHC class II , Mac-1 , and B220  cells by nega-
tive selection using sheep anti–rat–coated Dynabeads (Dynal). The resulting
CD4  enriched population was stained with Cy-Chrome–conjugated anti-CD4,
FITC-conjugated anti-CD45RB, allophycocyanin-conjugated anti-CD8 ,
biotinylated anti-CD25 mAb, and streptavidin-PE. Subpopulations of
CD4  cells were isolated by cell sorting on a FACSVantage (BD Biosciences)
or MoFlow High performance Cell Sorter (DakoCytomation).
T cell transfer model of colitis. RAG-1    or C.B-17 SCID mice
were injected i.p. with sorted CD4  T cell populations as described previ-
ously (44). Mice received purified CD4 CD45RBhigh T cells alone or in
combination with CD4 CD25  T cells as specified. Some mice received
CD4 CD25  T cells alone. In addition, some mice also received 2.0 mg of
anti–TGF-  mAb (clone 1D11.16.8) injected i.p. in PBS 1 d after T cell re-
constitution and then once a week for the duration of the experiment. After
T cell reconstitution, mice were weighed weekly and inspected for clinical
signs of disease. Mice presenting clinically severe disease were killed accord-
ing to the UK Animals Scientific Procedures Act of 1986.
Histological examination. Colons were removed and paraffin embed-
ded sections were cut and stained with hematoxylin and eosin. Inflamma-
tion was scored in a blinded fashion, on a scale of 0–4 (6): grade 0–1, no
colitis; grade 2, moderate colitis; and grades 3–4: severe colitis.
Cell preparation and flow cytometry. For analysis of surface marker
expression, cells from the spleen and thymus were stained with fluoro-
chrome-conjugated antibodies. Single cell suspensions were depleted of
erythrocytes by hypotonic lysis and labeled with the required antibodies.
For analysis of colitogenic effector populations, lamina propria (LP) lym-
phocytes were purified as described previously (45). In brief, colons were
cut into 0.5–1.0 cm pieces and incubated in PBS/10% FCS/5.0 mM EDTA
to remove the epithelial layer. The remaining tissue was further digested
with collagenase/dispase (Sigma-Aldrich), and the released lymphocytes
were recovered by centrifugation on a Percoll gradient (Amhersam Bio-
sciences). This resulting population was stained for expression of CD4,
CD45.2, and TCR-  chain, and the proportion of CD4  T cells were de-
termined by flow cytometric analysis on a FACSort using CELLQuest soft-
ware (BD Biosciences). For detection of cytokines, LP lymphocytes were
cultured overnight in complete medium in wells coated with 10  g/ml
anti–mouse CD3 . 10  g/ml brefeldin A (Sigma-Aldrich) was added for
the final 2 h of incubation, and surface and cytoplasmic staining was per-
formed as described previously (46). Labeled cells were analyzed on a FAC-
Sort or FACSCalibur using CELLQuest software.
Quantitative PCR. RNA was purified from sorted cells using Tri Re-
agent (Sigma-Aldrich) and reverse transcribed into cDNA using oligo-dT
and Superscript First Strand synthesis system (Invitrogen) according to the
manufacturer’s instructions. Quantitative real-time PCR was performed us-
ing the following primers and probes: FoxP3, 5 -TTCTCACAACCAG-
GCCACTTG-3 , 5 -CCCAGGAAAGACAGCAACCTT-3 , and 5 -
FAM-ATCCTACCCACTGCTGGCAAATGGAGTC-TAMRA-3 ; CD3 ,
5 -CACCAAGAGCAAGGAAGAAGATG-3 , 5 -TTACAGAATGTGT-
GAAAACTGCATTG-3 , and 5 -VIC-ACATAGGCACCATATCCG-
GCTTTATCTTCG-TAMRA-3 , using a Chromo4 Detector (MJ Re-
search). The reference cDNA sample used to make standard curves was
obtained from CD4-enriched splenocytes. Samples were analyzed in tripli-
cate and normalized levels of FoxP3 were calculated as the relative quantity
of FoxP3 divided by the relative quantity of CD3  in each sample, multi-
plied by 104.
Immunohistology. Tissue samples were snap frozen, cryocut, and ace-
tone fixed. Slides were blocked with donkey serum (Sigma-Aldrich). Tissue
sections were stained for CD4 (clone RMA4-5 FITC conjugated; BD Bio-
sciences) and FoxP3. FoxP3 staining was performed using rabbit polyclonal
anti–mouse FoxP3 antibodies (provided by F. Ramsdell, Zymogenetics, Se-
attle, WA; reference 47) and donkey anti–rabbit IgG Cy5 (Jackson Immu-
noResearch Laboratories). The specificity of FoxP3 staining has been con-
firmed by the absence of nuclear staining in organs from FoxP3    mice
(unpublished data).
Statistical analysis. The Mann-Whitney U test was used for comparison
of weight, clinical scores, cell numbers, and frequencies of cell surface mark-
ers. Differences were considered statistically significant when P   0.05.
Online supplemental material. Fig. S1 shows the flow cytometric anal-
ysis of T cell subsets from spleen and thymus of WT and dnT RII mice.
Fig. S2 depicts the T cell proliferation assay. FACS-sorted CD4  T cell sub-
sets were cultured in 96-well plates in RPMI 1640 containing 10% FCS, 2
mM L-glutamine, 0.05 mM 2-mercaptoethanol, and 100 U of penicillin
and streptomycin. 2.5   104 WT CD4 CD45RBhigh cells were cultured
with increasing numbers of CD4 CD25  cells from either WT or dnT-
 RII Tg mice together with  -irradiated T cell–depleted splenocytes as
APCs and anti-CD3  antibody. After 72 h, cells were pulsed with 0.5  Ci
[3H]thymidine (Amersham Biosciences) and harvested onto glass fiber filters
18 h later. Proliferation was measured using liquid scintillation counting.
Fig. S3 shows relative FoxP3 mRNA levels from splenic CD4 CD25  cells
from DO11.10.TGF- 1    or DO11.10.TGF- 1    mice. Online supple-
mental material is available at http://www.jem.org/cgi/content/full/jem.
20040685/DC1.
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